Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?

Gustafsson, 2008, Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy, Int J Oncol, 33, 1121 Modlin, 2003, A 5-decade analysis of 13,715 carcinoid tumors, Cancer, 97, 934, 10.1002/cncr.11105 Hemminki, 2001, Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden, Int J Cancer, 94, 444, 10.1002/ijc.1473 Newton, 1994, The epidemiology of carcinoid tumors in England and Scotland, Br J Cancer, 70, 939, 10.1038/bjc.1994.424 Niederle, 2010, Gastro-entero-pancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters, Endocr Relat Cancer, 17, 909, 10.1677/ERC-10-0152 Noronha, 2010, Well-differentiated neuroendocrine (carcinoid) tumors of the extrahepatic biliary ducts, Arch Pathol Lab Med, 134, 1075, 10.5858/2008-0764-RS.1 Spigel, 2009, Neuroendocrine carcinoma of unknown primary site, Semin Oncol, 36, 52, 10.1053/j.seminoncol.2008.10.003 Reubi, 2005, Candidates for peptide receptor radiotherapy today and in the future, J Nucl Med, 46 Oberg, 2009, Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors, Expert Rev Anticancer Ther, 9, 557, 10.1586/era.09.26 Ito, 2012, Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor, Invest New Drugs Grozinsky-Glasberg, 2012, New drugs in the therapy of neuroendocrine tumors, J Endocrinol Invest, 35, 930 Kulaksiz, 2002, Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumors with subtype specific antibodies, Gut, 50, 52, 10.1136/gut.50.1.52 Van Essen, 2007, Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumors, Acta Oncol, 46, 723, 10.1080/02841860701441848 Kaltsas, 2005, Treatment of advanced neuroendocrine tumors with radiolabelled somatostatin analogues, Endocr Relat Cancer, 12, 683, 10.1677/erc.1.01116 Bodei, 2009, Peptide receptor therapies in neuroendocrine tumors, J Endocrinol Invest, 32, 360, 10.1007/BF03345728 Teunissen, 2011, Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours, Endocr Relat Cancer, 18, S27, 10.1530/ERC-10-0282 Pfeifer, 2011, Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland, Neuroendocrinology, 93, 189, 10.1159/000324096 Muros, 2009, Outcome of treating advanced neuroendocrine tumors with radiolabelled somatostatin analogues, Clin Transl Oncol, 11, 48, 10.1007/s12094-009-0310-5 Grozinsky-Glasberg, 2011, Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas, Cancer, 117, 1377, 10.1002/cncr.25646 Forrer, 2007, Neuroendocrine tumors. Peptide receptor radionuclide therapy, Best Pract Res Clin Endocrinol Metab, 21, 111, 10.1016/j.beem.2007.01.007 Teunissen, 2004, Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate, J Clin Oncol, 22, 2724, 10.1200/JCO.2004.10.016 Kwekkeboom, 2008, Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival, J Clin Oncol, 26, 2124, 10.1200/JCO.2007.15.2553 Faiss, 2003, J Clin Oncol., 21, 2689, 10.1200/JCO.2003.12.142 Kwekkeboom, 2005, Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors, J Clin Oncol, 23, 2754, 10.1200/JCO.2005.08.066 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 O’Donoghue, 1995, Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides, J Nucl Med, 36, 1902 de Jong, 2001, Tumor response after [(90)Y-DOTA(0),Tyr(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size, J Nucl Med, 42, 1841 Liu, 1996, Thymocyte apoptosis in response to low-dose radiation, Mutat Res, 358, 185, 10.1016/S0027-5107(96)00119-4 Oberg, 2008, Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, 19, ii104, 10.1093/annonc/mdn117 Al-Nahhas, 2007, Gallium-68 PET: a new frontier in receptor cancer imaging, Anticancer Res, 27, 4087 Putzer, 2013, Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide, Eur J Nucl Med Mol Imaging, 40, 364, 10.1007/s00259-012-2286-6 Gupta, 2012, Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE, Cancer Biother Radiopharm, 27, 593, 10.1089/cbr.2012.1195 Behr, 1998, Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations, Eur J Nucl Med, 25, 201, 10.1007/s002590050216 Rolleman, 2003, Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine, Eur J Nucl Med Mol Imaging, 30, 9, 10.1007/s00259-002-0982-3 Zhernosekov, 2007, Processing of generator-produce 68Ga for medical application, J Nucl Med, 48, 1741, 10.2967/jnumed.107.040378 Hanley, 1982, Maximum attainable discrimination and the utilization of radiologic examinations, J Chronic Dis, 35, 601, 10.1016/0021-9681(82)90012-1 Krenning, 2005, Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy, J Nucl Med, 46 Kwekkeboom, 1997, Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview, Eur Radiol, 7, 1103, 10.1007/s003300050262 Kaltsas, 2002, Treatment of advanced neuroendocrine tumors using combination chemotherapy with lomustine and 5-fluorouracil, Clin Endocrinol, 57, 169, 10.1046/j.1365-2265.2002.01589.x Waldherr, 2002, Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC, J Nucl Med, 43, 610 Paganelli, 2002, 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies, Biopolymers, 66, 393, 10.1002/bip.10349 Kwekkeboom, 2005, Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs, J Nucl Med, 46, 62S Koukouraki, 2006, Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumors scheduled for 90Y-DOTATOC therapy, Eur J Nucl Med Mol Imaging, 33, 1115, 10.1007/s00259-006-0110-x Gabriel, 2009, 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy, J Nucl Med, 50, 1427, 10.2967/jnumed.108.053421 Miederer, 2009, Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT, Eur J Nucl Med Mol Imaging, 36, 48, 10.1007/s00259-008-0944-5 Boellaard, 2010, FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, Eur J Nucl Med Mol Imaging, 37, 181, 10.1007/s00259-009-1297-4 Baum, 2006, Monitoring treatment, 57 Oh, 2011, Effect of Peptide Receptor Radionuclide Therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT, Int J Mol Imaging, 2011, 524130, 10.1155/2011/524130